Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2026)
Bicycle Therapeutics (BCYC) reported Cash from Financing Activities of -$54000.0 for Q1 2026, down 31.71% on a YoY basis from -$79071.4 in Q1 2025, and down 260.0% quarter-over-quarter from -$15000.0 in Q4 2025.
Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at -$54000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 31.71% year-over-year to -$54000.0; the trailing twelve-month figure through Mar 2026 stood at -$144000.0 (down 100.03% YoY), and the FY2025 full-year result was -$131000.0, down 100.03% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$54000.0, down from -$15000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $549.6 million in Q2 2024, with the low at -$31.9 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $45.7 million across 5 years, with a median of $203000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 147466.67% — and 2024, when it tumbled 113.61%.
- Bicycle Therapeutics' Cash from Financing Activities stood at $5.9 million in 2022, then sank by 93.44% to $386000.0 in 2023, then slumped by 47.41% to $203000.0 in 2024, then slumped by 107.39% to -$15000.0 in 2025, then slumped by 260.0% to -$54000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$54000.0 (Q1 2026), -$15000.0 (Q4 2025), and -$30000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -54,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54,000.00 |
| Mar 31, 2026 | -54,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -45,000.00 |
| Jun 30, 2025 | -45,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Sep 30, 2024 | -31.93 Mn |
| Sep 30, 2024 | -31.93 Mn |
| Jun 30, 2024 | 549.61 Mn |
| Jun 30, 2024 | 549.61 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | 386,000.00 |
| Dec 31, 2023 | 386,000.00 |